As an alternative pharmacological strategy, inactivating ANGPTL4 specifically in the liver holds considerable promise.16 Despite these challenges, targeting ANGPTL4 presents a promising opportunity, as it may not only lower TG and remnant cholesterol but also redirect lipids away from ectopic sites and towards adipose tissue, potentially protecting against Type 2 diabetes.17 This evidence concerns the gene ANGPTL4 and type 2 diabetes mellitus.